🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseALT normalization rates on GLP-1 — looking for input Page 5

ALT normalization rates on GLP-1 — looking for input

bbq_ray_KC Mon, Apr 27, 2026 at 9:54 AM 24 replies 793 viewsPage 5 of 5
SkepticalSean
Member
98
345
Jan 2025
Maine
Apr 30, 2026 at 3:20 PM#21
quinn_sf said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

Correct as far as it goes. The part it does not cover is what to do when the honest answer is "not enough data", which is more often than anyone likes.

33 6DerekSJ_a1c, paige_pharma, emma_london and 30 others
Reply Quote Save Share Report
sarah_TO
Member
278
1,234
Sep 2024
Toronto, CA
May 1, 2026 at 12:41 AM#22
quinn_sf said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

Thank you for spelling out the reasoning rather than just the conclusion. I will report back once I have actually tried it.

34 7Dr.EndoEP, GraceAZ_72, carl_compliance and 31 others
Reply Quote Save Share Report
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
May 1, 2026 at 10:02 AM#23

Clinical perspective, offered as context rather than as advice. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

35 8tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 32 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
May 1, 2026 at 7:22 PM#24
Dr.CardioMD said:
The mechanism and the magnitude are separate questions.

Second this.

36 9SaraMom3, Dr.MetabolicMD, RetaRick_CA and 33 others
Reply Quote Save Share Report
Dr.EM_Chicago
Member
567
2,567
May 2024
Chicago, IL
May 2, 2026 at 4:42 AM#25
Dr.CardioMD said:
The mechanism and the magnitude are separate questions.

There is a second half to this that has not been said yet. There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

Last edited: May 2, 2026 at 8:42 AM
37 10lisa_labSD, adam_van, Dr.SurgeonPGH and 34 others
Reply Quote Save Share Report
1345

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register